Here are the DEF 14A proxy statements from Arcus Biosciences, Inc. (RCUS) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow RCUS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RCUS filings page.
Arcus Biosciences is holding its 2026 Annual Meeting as a fully virtual event on June 11, 2026, at 8:30 a.m. Pacific Time. Stockholders of record as of April 16, 2026, when 125,628,682 common shares were outstanding and entitled to vote, may participate online.
Investors will vote on three items: electing four Class II directors to serve until the 2029 meeting, ratifying Ernst & Young LLP as independent auditor for the 2026 fiscal year, and approving on an advisory basis the compensation of named executive officers. The board recommends voting in favor of all three proposals.
The filing outlines Arcus’s governance structure, including a majority-independent board, a lead independent director, specialized audit, compensation, nominating, and science committees, and policies such as a clawback policy, equity administration policy, and insider trading restrictions.